109 results about "Polyribonucleotides" patented technology

The present disclosure provides a method for analyzing a polyribonucleotide, wherein the polyribonucleotide is an mRNA molecule with a poly(A) tail, said method comprising: (a) obtaining a labeled polyribonucleotide by GI tailing; followed by (b) providing a second molecule comprising a first primer recognition sequence followed by a sequence of C nucleotide residues linked to a sequence of T nucleotide residues; followed by (c) obtaining a complex of said labeled polyribonucleotide and said second molecule; followed by (d) obtaining an extended second molecule by (d1) extending the 3′ end of the second molecule by synthesizing a sequence that is complementary to the labeled polyribonucleotide; followed by (d2) extending the 3′ end of the second molecule by adding at least 1 to 5 C nucleotide residues, followed by a second primer recognition sequence; said method providing information on entire polyribonucleotides, in particular mRNA isoforms and their respective poly(A) tails.

The present disclosure relates to compositions and methods for separating and / or purifying polyribonucleotides. The polyribonucleotide may be separated from a mixture of polyribonucleotides with an oligonucleotide that hybridizes to a target region of the polyribonucleotide and be available for use as a therapeutic agent.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The present disclosure relates, generally, to methods for producing, purifying, and using circular RNA from a prokaryotic system.

This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Disclosed herein include methods, compositions, and kits suitable for use in the measurement of the states of living cells across time and for use in the delivery of polyribonucleotides and circuits. There are provided, in some embodiments, RNA exporter proteins comprising an RNA-binding domain, a membrane-binding domain, and an interaction domain capable of nucleating self-assembly. Disclosed herein include polynucleotides encoding reporter RNA molecule(s) or cargo RNA molecule(s). In some embodiments, a plurality of RNA exporter proteins are capable of self-assembling into lipid-enveloped nanoparticles (LNs) secreted from a cell in which the RNA exporter proteins are expressed, thereby generating a population of LNs comprising exported reporter RNA molecule(s) or a fusogen and exported cargo RNA molecule(s). Disclosed herein include export modulator proteins capable of, e.g., enhancing or suppressing LN export.

This invention relates generally to devices, systems, and methods for the preparation and processing of circular polyribonucleotides comprising the use of a pressurization device comprising a reservoir comprising (a) a filtrate chamber and a (b) waste collection chamber separated by (c) a filter; the reservoir further comprising (d) a removable cap in contact with a pressure inlet port; wherein the device is in fluidic communication with a positive pressure source.

The present disclosure relates to compositions and methods for separating and / or purifying polyribonucleotides. The polyribonucleotide may be separated from a mixture of polyribonucleotides with an oligonucleotide that hybridizes to a target region of the polyribonucleotide.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding an immunogen and a multimerization domain useful in the development and production of vaccines.

The present disclosure is directed to methods for the enrichment of circular polyribonucleotides (circRNA), e.g., from population of polyribonucleotides containing circRNA and linear polyribonucleotides (linRNA), where the enrichment is performed under denaturing conditions. Also disclosed are compositions including a population of polyribonucleotides containing circRNA and linRNA in a solution under denaturing conditions. Further within the scope of the present disclosure are compositions containing an enriched population of circRNA, such as a composition that was produced by exposing the composition to one or more denaturing conditions.

The disclosure provides compositions, pharmaceutical preparations, and uses of circular polyribonucleotides complexed with one or more targeting moieties. The disclosure further discloses methods of using targeting moieties complexed with a circular polyribonucleotide to achieve functional delivery of a polypeptide to a cell.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding a plurality of immunoglobulin chains of anti-HIV antibody agents.

The present disclosure describes methods, kits, and systems for digesting polyribonucleotides. The methods involve selectively forming an oligonucleotide (e.g., DNA: RNA or RNA: RNA) duplex with a single-stranded target RNA, and then selectively cleaving the target RNA into smaller fragments using a sequence-specific nuclease that acts only on the RNA within the duplex. Additional sequence-specific ribonucleases can be used to provide additional cleavage of the target RNA at a predetermined site. By forming double strands to increase the availability of nuclease enzymes that can be used to cleave the single-stranded target RNA and to selectively control the location at which the target RNA is cleaved, the target RNA can be digested into fragments within a controllable size range that are optimal for polynucleotide analysis, such as by liquid chromatography and mass spectrometry.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

The present disclosure provides circular polyribonucleotides including a sequence including: a circularization element; a first spacer; an internal ribosome entry site (IRES) sequence; a sequence encoding a polypeptide; and a second spacer, where the sequence encoding the polypeptide has been codon-optimized to reduce the number of uracil ribonucleotides and / or reduce or remove TLR7- and TLR8-recognition motifs, and kits and compositions thereof. The present disclosure also provides methods of treating subjects in need thereof with the circular polyribonucleotides and compositions described herein.

The present disclosure relates to a method for enriching circular polyribonucleotides (circRNAs) from a population of polyribonucleotides, for example, comprising circRNAs and linear polyribonucleotides (linRNAs), wherein the enrichment is performed under denaturing conditions. Also disclosed is a composition comprising a population of polyribonucleotides comprising circRNAs and linRNAs in a solution under denaturing conditions.Furthermore, the scope of the present disclosure includes a composition comprising an enriched population of circRNAs, such as a composition produced by exposing the composition to one or more denaturing conditions.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

To provide pharmaceutical compositions and preparations of modified circular polyribonucleotides, and to provide uses thereof.SOLUTION: The present disclosure provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and a circular polyribonucleotide comprising a first portion of contiguous unmodified nucleotides. In some embodiments, the circular polyribonucleotide comprises at least one modified polyribonucleotide and a first portion of contiguous unmodified nucleotides. In some embodiments, the modified circular polyribonucleotide is delivered to a subject.SELECTED DRAWING: None